Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)

Next Previous
X
Search
Trial Profile

A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hyaluronidase (Primary) ; Immune globulin (Primary)
  • Indications Immunodeficiency disorders; Primary immunodeficiency diseases
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Takeda

    • Most Recent Events

    • 27 Dec 2024 According to a Takeda media release, company announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA in patients with agammaglobulinemia or hypogammaglobulinemia based on the data of NCT05150340, NCT05513586, NCT00814320 and NCT01175213 studies.
    • 05 Sep 2023 Status changed from recruiting to active, no longer recruiting.
    • 22 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top